InvestWiser

Biosergen AS

BIOSGNNasdaq StockholmHealthcareMarket value 41 m SEK
0.49SEK −0.4%
last day · Price as of 22 October 2026

The answer first

Does Biosergen beat the market?

No, Biosergen has not beaten the market over the last year.

Biosergen−99.0%Stockholm (OMXSGI)+14.5%

Max for seven days

Follow Biosergen with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 22 October 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Biosergen

From today, at a price of 0.49 SEK. Write why you follow Biosergen, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Biosergen

Your first answer is free, no account needed.

Do you own Biosergen, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Biosergen and a few more. Free, no card.

Past year against the exchange and Super Stock
Biosergen−99.0%Stockholm (OMXSGI)+14.5%Super Stock+47.8%
21 October 202522 October 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Biosergen has fallen 99.0% over the past year, including dividends.
  • The largest fall over the past three years was 99.5%. The price is 99.9% below its peak now.

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

Quality–
The company · Fundamentals: the accounts
  • Debt to equityBorrowings divided by equity4.29
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−347.0%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value–
The price · Valuation: the multiples
  • P/BPrice divided by equity1.6
  • P/SPrice divided by sales82.0
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend–
The share price · Technical: the price trend
  • 3 months−92.4%
  • 6 months−95.0%
  • 9 months−98.8%
  • 12 months−99.0%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−9.4%
3 years, per year
−81.2%
5 years, per year
−74.2%
Year to date
−98.8%
Largest fall, 3 years
−99.5%
From a peak to the bottom
From the peak now
−99.9%
How far the price is from the peak
Volatility, 1 year
82.4%
How much the price swings over a year
Beta, 1 year
−0.36
How much the price moves when the market moves

Return with dividends reinvested.

About Biosergen

Biosergen AS is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 1 employees.

Biosergen AB (publ), a biotech company, develops antifungal drugs. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.

See the full analysis of Biosergen.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market